Nanotechnology-based gene-eluting stents

Molecular Pharmaceutics

Volumn 10, Issue 4, 2013, Pages 1279-1298

  Goh, Debbie ^a,b   Tan, Aaron ^a,b   Farhatnia, Yasmin ^a   Rajadas, Jayakumar ^c   Alavijeh, Mohammad S ^d   Seifalian, Alexander M ^a,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Pharmidex Pharmaceutical Services Ltd   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

gene eluting stents; interventional cardiology; nanotechnology; regenerative medicine

Indexed keywords

CYCLOOXYGENASE 1; GANCICLOVIR; GREEN FLUORESCENT PROTEIN; NAKED DNA; PLASMID DNA; POLYMER; PROSTACYCLIN; SOLID LIPID NANOPARTICLE; THROMBOXANE A2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN C;

ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BARE METAL STENT; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DRUG ELUTING STENT; GENE ELUTING STENT; GENE TARGETING; GENE TRANSFER; GENE VECTOR; HUMAN; HYPERPLASIA; NANOTECHNOLOGY; NEOINTIMA; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; STENT; STENT THROMBOSIS; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL MOVEMENT; CELL PROLIFERATION; COATED MATERIALS, BIOCOMPATIBLE; DRUG-ELUTING STENTS; FIBRINOLYTIC AGENTS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; NANOTECHNOLOGY; PLASMIDS; POLYMERS; REGENERATIVE MEDICINE;

EID: 84875770273     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3006616     Document Type: Review

References (97)

1. Robertson, K. E.; McDonald, R. A.; Oldroyd, K. G.; Nicklin, S. A.; Baker, A. H. Prevention of coronary in-stent restenosis and vein graft failure: Does vascular gene therapy have a role? Pharmacol. Ther. 2012, 136, 23-34
2. Brito, L. A.; Chandrasekhar, S.; Little, S. R.; Amiji, M. M. In vitro and in vivo studies of local arterial gene delivery and transfection using lipopolyplexes-embedded stents J. Biomed. Mater. Res., Part A 2010, 93, 325-36
3. Fishbein, I.; Alferiev, I. S.; Nyanguile, O.; Gaster, R.; Vohs, J. M.; Wong, G. S.; Felderman, H.; Chen, I.-W.; Choi, H.; Wilensky, R. L.; Levy, R. J. Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 159-64
4. Muhs, A.; Heublein, B.; Schletter, J.; Herrmann, A.; Rüdiger, M.; Sturm, M.; Grust, A.; Malms, J.; Schrader, J.; Von der Leyen, H. E. Preclinical evaluation of inducible nitric oxide synthase lipoplex gene therapy for inhibition of stent-induced vascular neointimal lesion formation Hum. Gene Ther. 2003, 14, 375-83
5. Lowe, H. C.; Oesterle, S. N.; Khachigian, L. M. Coronary in-stent restenosis: Current status and future strategies J. Am. Coll. Cardiol. 2002, 39, 183-193
6. Brito, L.; Amiji, M. Nanoparticulate carriers for the treatment of coronary restenosis Int. J. Nanomed. 2007, 2, 143-61
7. Brito, L. A.; Chandrasekhar, S.; Little, S. R.; Amiji, M. M. Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis Biomed. Eng. Online 2010, 9, 56
8. Kim, T. G.; Lee, Y.; Park, T. G. Controlled gene-eluting metal stent fabricated by bio-inspired surface modification with hyaluronic acid and deposition of DNA/PEI polyplexes Int. J. Pharm. 2010, 384, 181-8
9. Sharif, F.; Hynes, S. O.; Cooney, R.; Howard, L.; McMahon, J.; Daly, K.; Crowley, J.; Barry, F.; O'Brien, T. Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis Mol. Ther. 2008, 16, 1674-80
10. Virmani, R.; Farb, A.; Guagliumi, G.; Kolodgie, F. D. Drug-eluting stents: caution and concerns for long-term outcome Coron. Artery Dis. 2004, 15, 313-8
11. Walter, D. H.; Cejna, M.; Diaz-Sandoval, L.; Willis, S.; Kirkwood, L.; Stratford, P. W.; Tietz, A. B.; Kirchmair, R.; Silver, M.; Curry, C.; Wecker, A.; Yoon, Y.-S.; Heidenreich, R.; Hanley, A.; Kearney, M.; Tio, F. O.; Kuenzler, P.; Isner, J. M.; Losordo, D. W. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis Circulation 2004, 110, 36-45
12. Egashira, K.; Nakano, K.; Ohtani, K.; Funakoshi, K.; Zhao, G.; Ihara, Y.; Koga, J.-I.; Kimura, S.; Tominaga, R.; Sunagawa, K. Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys Arterioscler., Thromb., Vasc. Biol. 2007, 27, 2563-8
13. Zhu, D.; Jin, X.; Leng, X.; Wang, H.; Bao, J.; Liu, W.; Yao, K.; Song, C. Local gene delivery via endovascular stents coated with dodecylated chitosan-plasmid DNA nanoparticles Int. J. Nanomed. 2010, 5, 1095-102
14. Takemoto, Y.; Kawata, H.; Soeda, T.; Imagawa, K.; Somekawa, S.; Takeda, Y.; Uemura, S.; Matsumoto, M.; Fujimura, Y.; Jo, J.; Kimura, Y.; Tabata, Y.; Saito, Y. Human placental ectonucleoside triphosphate diphosphohydrolase gene transfer via gelatin-coated stents prevents in-stent thrombosis Arterioscler., Thromb., Vasc. Biol. 2009, 29, 857-62
15. Sharif, F.; Hynes, S. O.; McCullagh, K. J. A.; Ganley, S.; Greiser, U.; McHugh, P.; Crowley, J.; Barry, F.; O'Brien, T. Gene-eluting stents: non-viral, liposome-based gene delivery of eNOS to the blood vessel wall in vivo results in enhanced endothelialization but does not reduce restenosis in a hypercholesterolemic model Gene Ther. 2012, 19, 321-8
16. Wang, K. Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model Mol. Ther. 2003, 7, 597-603
17. Sharif, F.; Daly, K.; Crowley, J.; O'Brien, T. Current status of catheter- and stent-based gene therapy Cardiovasc. Res. 2004, 64, 208-16
18. Katz, M. G.; Fargnoli, A. S.; Pritchette, L. A.; Bridges, C. R. Gene delivery technologies for cardiac applications Gene Ther. 2012, 19, 659-69
19. Rutanen, J.; Markkanen, J.; Ylä-Herttuala, S. Gene therapy for restenosis: current status Drugs 2002, 62, 1575-85
20. Fishbein, I.; Stachelek, S. J.; Connolly, J. M.; Wilensky, R. L.; Alferiev, I.; Levy, R. J. Site specific gene delivery in the cardiovascular system J. Controlled Release 2005, 109, 37-48
21. Fishbein, I.; Alferiev, I.; Bakay, M.; Stachelek, S. J.; Sobolewski, P.; Lai, M.; Choi, H.; Chen, I.-W.; Levy, R. J. Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries Circulation 2008, 117, 2096-103
22. Bennett, M. R.; Schwartz, S. M. Antisense Therapy for Angioplasty Restenosis: Some Critical Considerations Circulation 1995, 92, 1981-93
23. Ohno, T.; Gordon, D.; San, H.; Pompili, V.; Imperiale, M.; Nabel, G.; Nabel, E. Gene therapy for vascular smooth muscle cell proliferation after arterial injury Science 1994, 265, 781-4
24. Guzman, R.; Hirschowitz, E. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 10732-6
25. Simari, R. D.; San, H.; Rekhter, M.; Ohno, T.; Gordon, D.; Nabel, G. J.; Nabel, E. G. Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries J. Clin. Invest. 1996, 98, 225-35
26. Akyürek, L. M.; Nallamshetty, S.; Aoki, K.; San, H.; Yang, Z. Y.; Nabel, G. J.; Nabel, E. G. Coexpression of guanylate kinase with thymidine kinase enhances prodrug cell killing in vitro and suppresses vascular smooth muscle cell proliferation in vivo Mol. Ther. 2001, 3, 779-86
27. Cao, H.; Meng, X.; Liu, D.; Zhao, X.; Ding, J. Killing effect of coexpressing cytosine deaminase and thymidine kinase on rat vascular smooth muscle cells Chin. Med. J. 2004, 117, 1464-70
28. Godin, B.; Sakamoto, J. H.; Serda, R. E.; Grattoni, A.; Bouamrani, A.; Ferrari, M. Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases Trends Pharmacol. Sci. 2010, 31, 199-205
29. Harrell, R. L.; Rajanayagam, M. A. S.; Doanes, A. M.; Guzman, R. J.; Hirschowitz, E. A.; Crystal, R. G.; Epstein, S. E.; Finkel, T. Inhibition of Vascular Smooth Muscle Cell Proliferation and Neointimal Accumulation by Adenovirus-Mediated Gene Transfer of Cytosine Deaminase Circulation 1997, 96, 621-7
30. Mano, T.; Luo, Z.; Suhara, T.; Smith, R. C.; Esser, S.; Walsh, K. Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions Hum. Gene Ther. 2000, 11, 1625-35
31. Sriram, V.; Patterson, C. Cell Cycle in Vasculoproliferative Diseases: Potential Interventions and Routes of Delivery Circulation 2001, 103, 2414-9
32. Bicknell, K. A.; Surry, E. L.; Brooks, G. Targeting the cell cycle machinery for the treatment of cardiovascular disease J. Pharm. Pharmacol. 2003, 55, 571-91
33. Koledova, V. V; Khalil, R. A. Ca2+, calmodulin, and cyclins in vascular smooth muscle cell cycle Circ. Res. 2006, 98, 1240-3
34. Morishita, R.; Gibbons, G. H.; Ellison, K. E.; Nakajima, M.; Zhang, L.; Kaneda, Y.; Ogihara, T.; Dzau, V. J. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 8474-8
35. Morishita, R.; Gibbons, G. H.; Kaneda, Y.; Ogihara, T.; Dzau, V. J. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery Gene 1994, 149, 13-9
36. Morishita, R.; Gibbons, G. H.; Ellison, K. E.; Nakajima, M.; Von der Leyen, H.; Zhang, L.; Kaneda, Y.; Ogihara, T.; Dzau, V. J. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides J. Clin. Invest. 1994, 93, 1458-64
37. Zhu, N. L.; Wu, L.; Liu, P. X.; Gordon, E. M.; Anderson, W. F.; Starnes, V. A.; Hall, F. L. Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation Circulation 1997, 96, 628-35
38. Kipshidze, N. N.; Kim, H. S.; Iversen, P.; Yazdi, H. A.; Bhargava, B.; New, G.; Mehran, R.; Tio, F.; Haudenschild, C.; Dangas, G.; Stone, G. W.; Iyer, S.; Roubin, G. S.; Leon, M. B.; Moses, J. W. Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model J. Am. Coll. Cardiol. 2002, 39, 1686-91
39. Kipshidze, N. N.; Iversen, P.; Kim, H.-S.; Yiazdi, H.; Dangas, G.; Seaborn, R.; New, G.; Tio, F.; Waksman, R.; Mehran, R.; Tsapenko, M.; Stone, G. W.; Roubin, G. S.; Iyer, S.; Leon, M. B.; Moses, J. W. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model Catheter. Cardiovasc. Interventions 2004, 61, 518-27
40. Lee, M.; Simon, A. D.; Stein, C. A.; Rabbani, L. E. Antisense strategies to inhibit restenosis Antisense Nucleic Acid Drug Dev. 1999, 9, 487-92
41. Yang, Z. Y.; Simari, R. D.; Perkins, N. D.; San, H.; Gordon, D.; Nabel, G. J.; Nabel, E. G. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 7905-10
42. Chen, D.; Krasinski, K.; Sylvester, A.; Chen, J.; Nisen, P. D.; Andrés, V. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery J. Clin. Invest. 1997, 99, 2334-41
43. Tanner, F.; Boehm, M.; Akyürek, L.; San, H. Differential effects of the cyclin-dependent kinase inhibitors p27Kip1, p21Cip1, and p16Ink4 on vascular smooth muscle cell proliferation Circulation 2000, 2022-5
44. Tsui, L. V.; Camrud, A.; Mondesire, J.; Carlson, P.; Zayek, N.; Camrud, L.; Donahue, B.; Bauer, S.; Lin, A.; Frey, D.; Rivkin, M.; Subramanian, A.; Falotico, R.; Gyuris, J.; Schwartz, R.; McArthur, J. G. p27-p16 Fusion Gene Inhibits Angioplasty-Induced Neointimal Hyperplasia and Coronary Artery Occlusion Circ. Res. 2001, 89, 323-8
45. Yonemitsu, Y.; Kaneda, Y.; Tanaka, S.; Nakashima, Y.; Komori, K.; Sugimachi, K.; Sueishi, K. Transfer of Wild-Type p53 Gene Effectively Inhibits Vascular Smooth Muscle Cell Proliferation In Vitro and In Vivo Circ. Res. 1998, 82, 147-56
46. Scheinman, M.; Ascher, E.; Kallakuri, S.; Hingorani, A.; Gade, P.; Sherman, M.; Seth, P.; Jacob, T. P53 gene transfer to the injured rat carotid artery promotes apoptosis Surgery 1999, 126, 863-8
47. Chang, M. W.; Barr, E.; Seltzer, J.; Jiang, Y. Q.; Nabel, G. J.; Nabel, E. G.; Parmacek, M. S.; Leiden, J. M. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product Science (New York, N.Y.) 1995, 267, 518-22
48. Morishita, R.; Gibbons, G. H.; Horiuchi, M.; Ellison, K. E.; Nakama, M.; Zhang, L.; Kaneda, Y.; Ogihara, T.; Dzau, V. J. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 5855-9
49. Kawauchi, M.; Suzuki, J.; Morishita, R.; Wada, Y.; Izawa, A.; Tomita, N.; Amano, J.; Kaneda, Y.; Ogihara, T.; Takamoto, S.; Isobe, M. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates Circ. Res. 2000, 87, 1063-8
50. Wills, K. N.; Mano, T.; Avanzini, J. B.; Nguyen, T.; Antelman, D.; Gregory, R. J.; Smith, R. C.; Walsh, K. Tissue-specific expression of an anti-proliferative hybrid transgene from the human smooth muscle alpha-actin promoter suppresses smooth muscle cell proliferation and neointima formation Gene Ther. 2001, 8, 1847-54
51. Perlman, H.; Suzuki, E.; Simonson, M.; Smith, R. C.; Walsh, K. GATA-6 induces p21(Cip1) expression and G1 cell cycle arrest J. Biol. Chem. 1998, 273, 13713-8
52. Maillard, L.; Van Belle, E.; Smith, R. C.; Le Roux, A.; Denéfle, P.; Steg, G.; Barry, J. J.; Branellec, D.; Isner, J. M.; Walsh, K. Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty Cardiovasc. Res. 1997, 35, 536-46
53. Smith, R. C.; Branellec, D.; Gorski, D. H.; Guo, K.; Perlman, H.; Dedieu, J. F.; Pastore, C.; Mahfoudi, A.; DeneÌfle, P.; Isner, J. M.; Walsh, K. p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene Genes Dev. 1997, 11, 1674-89
54. Perlman, H.; Luo, Z.; Krasinski, K.; Le Roux, A.; Mahfoudi, A.; Smith, R. C.; Branellec, D.; Walsh, K. Adenovirus-mediated delivery of the Gax transcription factor to rat carotid arteries inhibits smooth muscle proliferation and induces apoptosis Gene Ther. 1999, 6, 758-63
55. Maillard, L.; Van Belle, E.; Tio, F. O.; Rivard, A.; Kearney, M.; Branellec, D.; Steg, P. G.; Isner, J. M.; Walsh, K. Effect of percutaneous adenovirus-mediated Gax gene delivery to the arterial wall in double-injured atheromatous stented rabbit iliac arteries Gene Ther. 2000, 7, 1353-61
56. Furman, C.; Luo, Z.; Walsh, K.; Duverger, N.; Copin, C.; Fruchart, J. C.; Rouis, M. Systemic tissue inhibitor of metalloproteinase-1 gene delivery reduces neointimal hyperplasia in balloon-injured rat carotid artery FEBS Lett. 2002, 531, 122-6
57. Puhakka, H. L.; Turunen, P.; Rutanen, J.; Hiltunen, M. O.; Turunen, M. P.; Yla-Herttuala, S. Tissue inhibitor of metalloproteinase 1 adenoviral gene therapy alone is equally effective in reducing restenosis as combination gene therapy in a rabbit restenosis model J. Vasc. Res. 2005, 42, 361-7
58. Turunen, M. P.; Puhakka, H. L.; Koponen, J. K.; Hiltunen, M. O.; Rutanen, J.; Leppänen, O.; Turunen, A.-M.; Närvänen, A.; Newby, A. C.; Baker, A. H.; Ylä-Herttuala, S. Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer Mol. Ther. 2002, 6, 306-12
59. Johnson, T. W.; Wu, Y. X.; Herdeg, C.; Baumbach, A.; Newby, A. C.; Karsch, K. R.; Oberhoff, M. Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries Arterioscler., Thromb., Vasc. Biol. 2005, 25, 754-9
60. Baker, A. H.; Edwards, D. R.; Murphy, G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities J. Cell Sci. 2002, 115, 3719-27
61. Dollery, C. M.; Humphries, S. E.; McClelland, A.; Latchman, D. S.; McEwan, J. R. Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury Circulation 1999, 99, 3199-205
62. Forough, R.; Koyama, N.; Hasenstab, D.; Lea, H.; Clowes, M.; Nikkari, S. T.; Clowes, A. W. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo Circ. Res. 1996, 79, 812-20
63. George, S. J. Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis Curr. Opin. Lipidol. 1998, 9, 413-23
64. Cohen-Sacks, H.; Najajreh, Y.; Tchaikovski, V.; Gao, G.; Elazer, V.; Dahan, R.; Gati, I.; Kanaan, M.; Waltenberger, J.; Golomb, G. Novel PDGFbetaR antisense encapsulated in polymeric nanospheres for the treatment of restenosis Gene Ther. 2002, 9, 1607-16
65. Carmeliet, P.; Moons, L.; Lijnen, R.; Janssens, S.; Lupu, F.; Collen, D.; Gerard, R. D. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice Circulation 1997, 96, 3180-91
66. Asahara, T.; Chen, D.; Tsurumi, Y.; Kearney, M.; Rossow, S.; Passeri, J.; Symes, J. F.; Isner, J. M. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer Circulation 1996, 94, 3291-302
67. Van Belle, E.; Maillard, L.; Tio, F. O.; Isner, J. M. Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimal formation Biochem. Biophys. Res. Commun. 1997, 235, 311-6
68. Hiltunen, M. O.; Laitinen, M.; Turunen, M. P.; Jeltsch, M.; Hartikainen, J.; Rissanen, T. T.; Laukkanen, J.; Niemi, M.; Kossila, M.; Hakkinen, T. P.; Kivela, A.; Enholm, B.; Mansukoski, H.; Turunen, A.-M.; Alitalo, K.; Yla-Herttuala, S. Intravascular Adenovirus-Mediated VEGF-C Gene Transfer Reduces Neointima Formation in Balloon-Denuded Rabbit Aorta Circulation 2000, 102, 2262-8
69. Rutanen, J.; Turunen, A.-M.; Teittinen, M.; Rissanen, T. T.; Heikura, T.; Koponen, J. K.; Gruchala, M.; Inkala, M.; Jauhiainen, S.; Hiltunen, M. O.; Turunen, M. P.; Stacker, S. A.; Achen, M. G.; Ylä-Herttuala, S. Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism Gene Ther. 2005, 12, 980-7
70. Leifeld, L.; Fielenbach, M.; Dumoulin, F.-L.; Speidel, N.; Sauerbruch, T.; Spengler, U. Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) expression in fulminant hepatic failure J. Hepatol. 2002, 37, 613-619
71. Vassalli, G.; Dichek, D. A. Gene therapy for arterial thrombosis Cardiovasc. Res. 1997, 35, 459-69
72. Zoldhelyi, P.; McNatt, J.; Xu, X.-M.; Loose-Mitchell, D.; Meidell, R. S.; Clubb, F. J.; Buja, L. M.; Willerson, J. T.; Wu, K. K. Prevention of Arterial Thrombosis by Adenovirus-Mediated Transfer of Cyclooxygenase Gene Circulation 1996, 93, 10-17
73. Wu, K. K. Prostacyclin and nitric oxide-related gene transfer in preventing arterial thrombosis and restenosis Agents Actions Suppl. 1997, 48, 107-23
74. Todaka, T.; Yokoyama, C.; Yanamoto, H.; Hashimoto, N.; Nagata, I.; Tsukahara, T.; Hara, S.; Hatae, T.; Morishita, R.; Aoki, M.; Ogihara, T.; Kaneda, Y.; Tanabe, T.; Faraci, F. M. Gene Transfer of Human Prostacyclin Synthase Prevents Neointimal Formation After Carotid Balloon Injury in Rats Editorial Comment Stroke 1999, 30, 419-26
75. Numaguchi, Y.; Okumura, K.; Harada, M.; Naruse, K.; Yamada, M.; Osanai, H.; Matsui, H.; Ito, M.; Murohara, T. Catheter-based prostacyclin synthase gene transfer prevents in-stent restenosis in rabbit atheromatous arteries Cardiovasc. Res. 2004, 61, 177-85
76. Shyue, S.; Tsai, M.; Liou, J.; Willerson, J. T.; Wu, K. K. Selective Augmentation of Prostacyclin Production by Combined Prostacyclin Synthase and Cyclooxygenase-1 Gene Transfer Circulation 2001, 103, 2090-5
77. Liu, Q.; Chen, Z.; Bobustuc, G. C.; McNatt, J. M.; Segall, H.; Pan, S.; Willerson, J. T.; Zoldhelyi, P. Local Gene Transduction of Cyclooxygenase-1 Increases Blood Flow in Injured Atherosclerotic Rabbit Arteries Circulation 2005, 111, 1833-40
78. Rade, J. J.; Schulick, A. H.; Virmani, R.; Dichek, D. A. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury Nat. Med. 1996, 2, 293-8
79. Zoldhelyi, P.; Chen, Z. Q.; Shelat, H. S.; McNatt, J. M.; Willerson, J. T. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4078-83
80. Yin, X.; Yutani, C.; Ikeda, Y.; Enjyoji, K.; Ishibashi-Ueda, H.; Yasuda, S.; Tsukamoto, Y.; Nonogi, H.; Kaneda, Y.; Kato, H. Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries Cardiovasc. Res. 2002, 56, 454-63
81. Ohtani, K.; Usui, M.; Nakano, K.; Kohjimoto, Y.; Kitajima, S.; Hirouchi, Y.; Li, X.-H.; Kitamoto, S.; Takeshita, A.; Egashira, K. Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys Gene Ther. 2004, 11, 1273-82
82. Klugherz, B. D.; Jones, P. L.; Cui, X.; Chen, W.; Meneveau, N. F.; DeFelice, S.; Connolly, J.; Wilensky, R. L.; Levy, R. J. Gene delivery from a DNA controlled-release stent in porcine coronary arteries Nat. Biotechnol. 2000, 18, 1181-4
83. Klugherz, B. D.; Song, C.; DeFelice, S.; Cui, X.; Lu, Z.; Connolly, J.; Hinson, J. T.; Wilensky, R. L.; Levy, R. J. Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus Human Gene Ther. 2002, 13, 443-54
84. Chorny, M.; Fishbein, I.; Alferiev, I. S.; Nyanguile, O.; Gaster, R.; Levy, R. J. Adenoviral gene vector tethering to nanoparticle surfaces results in receptor-independent cell entry and increased transgene expression Mol. Ther. 2006, 14, 382-91
85. Vorburger, S. A.; Hunt, K. K. Adenoviral gene therapy Oncologist 2002, 7, 46-59
86. Perlstein, I.; Connolly, J.; Cui, X.; Song, C.; Li, Q. DNA delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid-controlled release coating: mechanisms of enhanced transfection Gene Ther. 2003, 10, 1420-1428
87. Wang, Y.; Yu, M.; Zhang, L.; Song, C.; Alferiev, I. S.; Levy, R. J. Immobilization of gene vectors on bisphosphonate-mediated gene-eluting metal stents using antibody for localized gene delivery J. Controlled Release 2011, 152 (Suppl.) e173-4
88. Martinez, A. W.; Chaikof, E. L. Microfabrication and nanotechnology in stent design Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2011, 3, 256-68
89. Jin, X.; Mei, L.; Song, C.; Liu, L.; Leng, X.; Sun, H.; Kong, D.; Levy, R. J. Immobilization of plasmid DNA on an anti-DNA antibody modified coronary stent for intravascular site-specific gene therapy J. Gene Med. 2008, 10, 421-9
90. Burke, S. E.; Kuntz, R. E.; Schwartz, L. B. Zotarolimus (ABT-578) eluting stents Adva. Drug Delivery Rev. 2006, 58, 437-46
91. Whelan, D. M.; Van der Giessen, W. J.; Krabbendam, S. C.; Van Vliet, E. A.; Verdouw, P. D.; Serruys, P. W.; Van Beusekom, H. M. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries Heart 2000, 83, 338-45
92. Huh, D.; Hamilton, G. A.; Ingber, D. E. From 3D cell culture to organs-on-chips Trends Cell Biol. 2011, 21, 745-54
93. Rashid, S. T.; Fuller, B.; Hamilton, G.; Seifalian, A. M. Tissue engineering of a hybrid bypass graft for coronary and lower limb bypass surgery FASEB J. 2008, 22, 2084-9
94. Chaloupka, K.; Motwani, M.; Seifalian, A. M. Development of a new lacrimal drainage conduit using POSS nanocomposite Biotechnol. Appl. Biochem. 2011, 58, 363-70
95. Elliott, M. J.; De Coppi, P.; Speggiorin, S.; Roebuck, D.; Butler, C. R.; Samuel, E.; Crowley, C.; McLaren, C.; Fierens, A.; Vondrys, D.; Cochrane, L.; Jephson, C.; Janes, S.; Beaumont, N. J.; Cogan, T.; Bader, A.; Seifalian, A. M.; Hsuan, J. J.; Lowdell, M. W.; Birchall, M. A. Stem-cell-based, tissue engineered tracheal replacement in a child: a 2-year follow-up study Lancet 2012, 380, 994-1000
96. Jungebluth, P.; Alici, E.; Baiguera, S.; Le Blanc, K.; Blomberg, P.; Bozóky, B.; Crowley, C.; Einarsson, O.; Grinnemo, K.-H.; Gudbjartsson, T.; Le Guyader, S.; Henriksson, G.; Hermanson, O.; Juto, J. E.; Leidner, B.; Lilja, T.; Liska, J.; Luedde, T.; Lundin, V.; Moll, G.; Nilsson, B.; Roderburg, C.; Strömblad, S.; Sutlu, T.; Teixeira, A. I.; Watz, E.; Seifalian, A.; Macchiarini, P. Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study Lancet 2011, 378, 1997-2004
97. Tan, A.; Alavijeh, M. S.; Seifalian, A. M. Next generation stent coatings: convergence of biotechnology and nanotechnology Trends Biotechnol. 2012, 30, 406-9